Replimune Group (NASDAQ:REPL) Now Covered by Analysts at Cantor Fitzgerald

Investment analysts at Cantor Fitzgerald started coverage on shares of Replimune Group (NASDAQ:REPL - Get Free Report) in a research note issued on Friday, MarketBeat.com reports. The brokerage set an "overweight" rating on the stock.

Several other analysts also recently commented on REPL. JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Piper Sandler increased their price objective on shares of Replimune Group from $14.00 to $22.00 and gave the company an "overweight" rating in a research report on Monday, June 2nd. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Replimune Group currently has an average rating of "Buy" and a consensus price target of $20.83.

Replimune Group Stock Down 0.4%

Shares of NASDAQ:REPL traded down $0.04 during midday trading on Friday, reaching $9.23. The company's stock had a trading volume of 794,173 shares, compared to its average volume of 853,939. The firm has a 50 day moving average of $8.87 and a 200-day moving average of $10.73. The firm has a market capitalization of $711.54 million, a P/E ratio of -3.01 and a beta of 0.63. The company has a quick ratio of 7.95, a current ratio of 7.95 and a debt-to-equity ratio of 0.17. Replimune Group has a 12-month low of $6.44 and a 12-month high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the previous year, the firm earned ($0.25) EPS. On average, research analysts anticipate that Replimune Group will post -2.97 earnings per share for the current year.

Insider Activity

In other news, CEO Sushil Patel sold 25,105 shares of the stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $202,346.30. Following the transaction, the chief executive officer now owns 343,576 shares in the company, valued at $2,769,222.56. This represents a 6.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Andrew Schwendenman sold 3,287 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total transaction of $26,460.35. Following the completion of the transaction, the chief accounting officer now owns 68,284 shares in the company, valued at $549,686.20. This trade represents a 4.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 74,907 shares of company stock valued at $603,655 in the last 90 days. 8.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Replimune Group

Several institutional investors have recently made changes to their positions in REPL. Rhumbline Advisers lifted its stake in shares of Replimune Group by 8.3% in the 4th quarter. Rhumbline Advisers now owns 95,465 shares of the company's stock worth $1,156,000 after purchasing an additional 7,317 shares during the period. New York State Common Retirement Fund lifted its stake in shares of Replimune Group by 260.8% in the 4th quarter. New York State Common Retirement Fund now owns 43,204 shares of the company's stock worth $523,000 after purchasing an additional 31,231 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Replimune Group by 7.3% in the 4th quarter. Bank of New York Mellon Corp now owns 174,518 shares of the company's stock worth $2,113,000 after purchasing an additional 11,893 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Replimune Group by 4.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 508,398 shares of the company's stock worth $6,157,000 after acquiring an additional 23,601 shares during the period. Finally, Victory Capital Management Inc. bought a new stake in Replimune Group during the 4th quarter worth approximately $543,000. Institutional investors own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.